中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
11期
716-719
,共4页
夏铀铀%王磊%宋大安%黎世秋%蒋晓东
夏鈾鈾%王磊%宋大安%黎世鞦%蔣曉東
하유유%왕뢰%송대안%려세추%장효동
食管癌%雷替曲塞%奥沙利铂%放射治疗%同步治疗%预后
食管癌%雷替麯塞%奧沙利鉑%放射治療%同步治療%預後
식관암%뢰체곡새%오사리박%방사치료%동보치료%예후
esophageal carcinoma%raltitrexed plus oxaliplatin%radiotherapy%concurrent therapy%prognosis
目的：初步评价中晚期食管癌患者应用雷替曲塞/奥沙利铂同步放疗的疗效、安全性。方法：54例采用食管癌非手术分期的Ⅱ～Ⅲ期食管癌患者，应用雷替曲塞/奥沙利铂方案联合放疗进行治疗。放疗剂量60 Gy/30次。雷替曲塞剂量为2.6 mg/m2，奥沙利铂剂量为100 mg/m2，均于放疗d1、d22应用。放疗期间行2周期化疗。结果：全组共9例（16.7%）获得完全缓解，部分缓解37例（68.5%），无缓解或病情进展8例（14.8%），有效率85.2%。1、2年局部控制率分别为75.4%和57.3%，1、2年生存率分别为70.4%（95%CI：0.6～0.8）、46.6%（95%CI：0.3～0.6）。患者的急性放射性食管炎、白细胞下降、急性腹泻、神经毒性发生率分别为100%、72.2%、16.7%、44.4%；不良反应≥3级分别为7.4%、7.4%、1.9%、0。结论：雷替曲塞联合奥沙利铂同步放疗对提高中晚期食管癌临床缓解率、生存率有一定意义，且不良反应轻，值得进一步大样本Ⅲ期临床研究。
目的：初步評價中晚期食管癌患者應用雷替麯塞/奧沙利鉑同步放療的療效、安全性。方法：54例採用食管癌非手術分期的Ⅱ～Ⅲ期食管癌患者，應用雷替麯塞/奧沙利鉑方案聯閤放療進行治療。放療劑量60 Gy/30次。雷替麯塞劑量為2.6 mg/m2，奧沙利鉑劑量為100 mg/m2，均于放療d1、d22應用。放療期間行2週期化療。結果：全組共9例（16.7%）穫得完全緩解，部分緩解37例（68.5%），無緩解或病情進展8例（14.8%），有效率85.2%。1、2年跼部控製率分彆為75.4%和57.3%，1、2年生存率分彆為70.4%（95%CI：0.6～0.8）、46.6%（95%CI：0.3～0.6）。患者的急性放射性食管炎、白細胞下降、急性腹瀉、神經毒性髮生率分彆為100%、72.2%、16.7%、44.4%；不良反應≥3級分彆為7.4%、7.4%、1.9%、0。結論：雷替麯塞聯閤奧沙利鉑同步放療對提高中晚期食管癌臨床緩解率、生存率有一定意義，且不良反應輕，值得進一步大樣本Ⅲ期臨床研究。
목적：초보평개중만기식관암환자응용뢰체곡새/오사리박동보방료적료효、안전성。방법：54례채용식관암비수술분기적Ⅱ～Ⅲ기식관암환자，응용뢰체곡새/오사리박방안연합방료진행치료。방료제량60 Gy/30차。뢰체곡새제량위2.6 mg/m2，오사리박제량위100 mg/m2，균우방료d1、d22응용。방료기간행2주기화료。결과：전조공9례（16.7%）획득완전완해，부분완해37례（68.5%），무완해혹병정진전8례（14.8%），유효솔85.2%。1、2년국부공제솔분별위75.4%화57.3%，1、2년생존솔분별위70.4%（95%CI：0.6～0.8）、46.6%（95%CI：0.3～0.6）。환자적급성방사성식관염、백세포하강、급성복사、신경독성발생솔분별위100%、72.2%、16.7%、44.4%；불량반응≥3급분별위7.4%、7.4%、1.9%、0。결론：뢰체곡새연합오사리박동보방료대제고중만기식관암림상완해솔、생존솔유일정의의，차불량반응경，치득진일보대양본Ⅲ기림상연구。
Objective:To evaluate the efficacy and safety of raltitrexed plus oxaliplatin combined with concurrent radiotherapy for advanced esophageal carcinoma. Methods:A total of 54 patients with stageⅡ/Ⅲadvanced esophageal carcinoma according to the clinical staging of esophageal carcinoma nonsurgical methods were treated with raltitrexed plus oxaliplatin combined with concurrent radiotherapy. The patients were irradiated with a dose of 60 Gy in 30 fractions. Two cycles of concurrent chemotherapy were adminis-tered during radiotherapy, with 100 mg/m2 oxaliplatin and 2.6 mg/m2 raltitrexed on d1 and d22. Results:The complete response rate was 16.7%(9/54), and the partial response rate was 68.5%(37/54). The total response rate was 85.2%. The no response and progression rate was 14.8%(8/54). The one-and two-year local control rates and overall survival rates were 75.4%, 57.3%and 70.4%(95%CI, 0.6-0.8), 46.6%(95%CI, 0.3-0.6), respectively. The incidence rates of radiation-induced esophagitis, leucopenia, acute diarrhea, neuro-toxicity were 100%, 72.2%, 16.7%, and 44.4%, of which 7.4%, 7.4%, 1.9%, and 0%were≥grade 3, respectively. Conclusion:Ralti-trexed plus oxaliplatin combined with concurrent radiotherapy can enhance the response rate and prolong the survival of patients with advanced esophageal carcinoma. The regime has mild toxicity and is worthy of further study in PhaseⅢ.
